Memantina Kern Pharma

Memantine Hydrochloride, the active ingredient in Memantina Kern Pharma, is an NMDA receptor antagonist presented as an oral formulation for systemic use. It is employed in the management of Alzheimer’s disease to help improve cognitive function and daily living activities in affected individuals.

GNH USA supplies Memantina Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability.

Memantine is an NMDA receptor antagonist used in the treatment of Alzheimer’s disease and related cognitive disorders. - Alzheimer's disease (moderate to severe): improves cognition, functional abilities, and may slow symptom progression. - Alzheimer's disease (mild to moderate): may delay worsening of memory and daily functioning. - Alzheimer's disease (as adjunct to cholinesterase inhibitors): enhances overall therapeutic response when combined with standard therapy.

Memantine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hallucinations or psychosis: visual or auditory disturbances. - Severe hypotension: marked drop in blood pressure.

When prescribing memantine, clinicians should consider several safety aspects to minimize risk. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic disease: monitor liver enzymes and use with caution. - History of seizures: observe for increased seizure activity. - Concomitant use with other NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store below 25°C: keep in the original container, protect from moisture and light.

Memantine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuropsychiatric adverse events. - High‑dose quinidine: may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): monitor for additive cognitive effects. - Proton pump inhibitors (e.g., omeprazole): may affect absorption, observe therapeutic response. - Diuretics (e.g., furosemide): watch for electrolyte disturbances that could predispose to seizures.